Generation of cardio-protective antibodies after pneumococcal polysaccharide vaccine: Early results from a randomised controlled trial
CONCLUSIONS: PPV engenders a long-lasting increase in anti-pneumococcal IgG, and to a lesser extent, IgM titres, as well as a transient increase in anti-OxLDL IgM antibodies. However, there were no detectable changes in surrogate markers of atherosclerosis at the 2-year follow-up. Long-term, prospective follow-up of clinical outcomes is continuing to assess if PPV reduces CVD events.PMID:35290813 | DOI:10.1016/j.atherosclerosis.2022.02.011
Source: Atherosclerosis - Category: Cardiology Authors: Shu Ren Philip M Hansbro Wichat Srikusalanukul Jay C Horvat Tegan Hunter Alexandra C Brown Roseanne Peel Jack Faulkner Tiffany-Jane Evans Shu Chuen Li David Newby Alexis Hure Walter P Abhayaratna Sotirios Tsimikas Ayelet Gonen Joseph L Witztum John Attia Source Type: research
More News: Australia Health | Cardiology | Cardiovascular | Heart | Heart Attack | Ischemic Stroke | Meningitis Vaccine | Pneomococcal Vaccine | Statistics | Stroke | Study | Vaccines